Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders
Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation.
Sensorion has entered into a broad strategic collaboration with the Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).
Company Details
- Employees
- 84
- Founded
- -
- Address
- 375, Rue Du Professeur Joseph Blayac, Montpellier,occitanie 34080,france
- Phone
- 33467207730
- co****@****rma.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- sensorion-pharma.com
- Keywords
- gene therapy, small molecule, inner ear.
- HQ
- Montpellier, Occitanie
Sensorion Questions
Sensorion's helpline number is 33467207730
Sensorion's website is sensorion-pharma.com
Sensorion's LinkedIn profile is https://fr.linkedin.com/company/sensorionph
Sensorion has
84 employees.
View email and phone details for 84
employees at Sensorion.
Sensorion's industry is
Biotechnology Research
Sensorion's top competitors are
Cilcare,
Azelead,
Aurion Biotech,
Id Solutions,
Medincell,
Medesis Pharma,
Nanobiotix,
Innate Pharma,
Acobiom,
Innovative Diagnostics.
Sensorion's support email address is contact@sensorion-pharma.com
Sensorion's categories are Biotechnology Research
Sensorion's founding year is 2009
